The India biosimilar market size was valued at INR 4.37 Billion in 2024, driven by the rising prevalence of chronic diseases across the region. The market is expected to grow at a CAGR of 14.20% during the forecast period of 2025-2034, with the values likely to rise from INR 16.49 Billion by 2034.
The region is gaining significant pharmaceutical attention to meet the high demand and it is heavily impacted by the rising investments to build the medical infrastructure and offer rapid, accurate and affordable outcomes to the patients. Dr. Reddy's Laboratories, a prominent pharmaceutical player in the region, has identified the biosimilar segment as a key priority area. This indicates the ongoing trend of rising emphasis on the area.
To push the production and application of biosimilars, the government has also eased out on stringent regulations and encouraging tie-ups between foreign and indigenous companies. In July 2023, India's Biocon Biologics launched a biosimilar version of AbbVie's rheumatoid arthritis drug Humira in the United States.
Biocon Biologics has also received the marketing authorization for Yesafili, an ophthalmology product which is a biosimilar to the reference product Eylea (Aflibercept) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). As a result, the India biosimilar market share is expected to have a significant global impact in coming years as well.
Acknowledging the need for pharma innovation in the country, the pharmaceutical department proposed a PRIP (Promotion of Research and Innovation in Pharma MedTech Sector) scheme in August 2023. This scheme outlays a budget of INR 5000 crores and is entirely focused on strengthening the research infrastructure in the country. Such initiatives are further projected to add to the India biosimilars market value.
However, some factors, such as negative perception from physicians, lower price differential as compared to small-molecule generics, patent extensions, and others, are hampering the growth of the market in India.
India overtaking China to become the most populous country in the world has also accelerated the India biosimilars market growth further. The growing geriatric population within the region has become an area of concern for the government. The patents of numerous biologic drugs have expired, and some of the blockbuster drugs are further expected to have their patent protection expire in the upcoming years, thus, offering tremendous market opportunities for biosimilar manufacturers in India in the forecast period.
This product will be delivered within 3-5 business days.
Biosimilar: Introduction
A biosimilar is a biologic medical product that is almost identical to an original product launched by a different company. They are also known as subsequent entry biologics (SEBs) or follow-on biologics. These are the approved versions of innovator products and can be manufactured when the patent of the original product expires. Biosimilars can make several expensive and critical treatments more accessible to more people as they may be more affordable or be available in bulk quantities.India Biosimilar Market Analysis
With the rising incidence of chronic diseases, the India biosimilar market demand has grown. As a result, there have been several significant initiatives from the private and state-owned organizations to mitigate the rising burden of morbidities.The region is gaining significant pharmaceutical attention to meet the high demand and it is heavily impacted by the rising investments to build the medical infrastructure and offer rapid, accurate and affordable outcomes to the patients. Dr. Reddy's Laboratories, a prominent pharmaceutical player in the region, has identified the biosimilar segment as a key priority area. This indicates the ongoing trend of rising emphasis on the area.
To push the production and application of biosimilars, the government has also eased out on stringent regulations and encouraging tie-ups between foreign and indigenous companies. In July 2023, India's Biocon Biologics launched a biosimilar version of AbbVie's rheumatoid arthritis drug Humira in the United States.
Biocon Biologics has also received the marketing authorization for Yesafili, an ophthalmology product which is a biosimilar to the reference product Eylea (Aflibercept) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). As a result, the India biosimilar market share is expected to have a significant global impact in coming years as well.
India Biosimilar Market Segmentation
India Biosimilar Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:Market Breakup by Product Class
- Monoclonal Antibodies
- Recombinant Hormones
- Immunomodulators
- Anti-Inflammatory Agents
- Other Product Classes
Market Breakup by Manufacturing Type
- In-House Manufacturing
- Contract Manufacturing
Market Breakup by Applications
- Blood Disorders
- Growth Hormonal Deficiency
- Chronic and Autoimmune Disorders
- Oncology
- Other Applications
India Biosimilar Market Overview
The growing demand for biosimilars due to their cost-effectiveness has been aiding the industry growth. The market is finding further impetus for its growth in the several cost-saving initiatives undertaken by governments as well as third-party payers, which, as a result, are encouraging the use of biosimilars as opposed to branded biologics, thereby propelling the demand for biosimilars.Acknowledging the need for pharma innovation in the country, the pharmaceutical department proposed a PRIP (Promotion of Research and Innovation in Pharma MedTech Sector) scheme in August 2023. This scheme outlays a budget of INR 5000 crores and is entirely focused on strengthening the research infrastructure in the country. Such initiatives are further projected to add to the India biosimilars market value.
However, some factors, such as negative perception from physicians, lower price differential as compared to small-molecule generics, patent extensions, and others, are hampering the growth of the market in India.
India overtaking China to become the most populous country in the world has also accelerated the India biosimilars market growth further. The growing geriatric population within the region has become an area of concern for the government. The patents of numerous biologic drugs have expired, and some of the blockbuster drugs are further expected to have their patent protection expire in the upcoming years, thus, offering tremendous market opportunities for biosimilar manufacturers in India in the forecast period.
India Biosimilar Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:- Pfizer Inc.
- Eli Lilly and Company
- Celltrion Healthcare
- Viatris Inc. (Mylan)
- Novartis AG
- Samsung Bioepis Co. Ltd.
- Stada Arzneimittel AG
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceutical Ltd.
- LG Life Sciences Inc.
- Biocon Limited
- Amgen Inc.
- Dr. Reddy's Laboratories
- Coherus Biosciences Inc.
- Biocad
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 India Biosimilar Market Overview
4 India Biosimilar Market Landscape
5 India Biosimilar Market Dynamics
6 India Biosimilar Market Segmentation
7 Patent Analysis
8 Grants Analysis
9 Partnership and Collaborations Analysis
11 Suppliers Landscape
12 India Biosimilar Market - Distribution Model (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
15 Payment Methods (Additional Insight)
